Combining Objective and Subjective Sedation Assessment Tools (COST_2)
This study has been completed.
Sponsor:
Duke University
Collaborator:
Covidien
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00734409
First received: June 3, 2008
Last updated: March 21, 2013
Last verified: August 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Results First Received: August 10, 2012
| Study Type: | Interventional |
|---|---|
| Study Design: | Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment |
| Condition: |
Critical Illness |
| Intervention: |
Device: Bispectral Index (BIS) Monitor |
Participant Flow
Recruitment Details
| Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations |
|---|
| Patients were in the Medical ICU or Neuro ICU at Duke University Hospital or the mixed ICU at Durham Regional. If patients met all inclusion criteria and no exclusion criteria, the attending was asked if patient's legally authorized representative (LAR) could be approached for consent. Enrollment started May of 2008 and closed April of 2011. |
Pre-Assignment Details
| Significant events and approaches for the overall study following participant enrollment, but prior to group assignment |
|---|
| Patients were only excluded from the trial after consent and prior to randomization if they no longer met inclusion criteria, for instance the medical team decided to remove sedatives. |
Reporting Groups
| Description | |
|---|---|
| RASS Plus BIS | Participants in this arm will receive sedation assessment with the RASS scale augmented with BIS monitoring. |
| RASS Only | Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution |
Participant Flow: Overall Study
| RASS Plus BIS | RASS Only | |
|---|---|---|
| STARTED | 155 | 145 |
| COMPLETED | 155 | 145 |
| NOT COMPLETED | 0 | 0 |
Baseline Characteristics
Reporting Groups
| Description | |
|---|---|
| RASS Plus BIS | Participants in this arm will receive sedation assessment with the RASS scale augmented with BIS monitoring. |
| RASS Only | Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution |
| Total | Total of all reporting groups |
Baseline Measures
| RASS Plus BIS | RASS Only | Total | |
|---|---|---|---|
|
Number of Participants
[units: participants] |
155 | 145 | 300 |
|
Age
[units: participants] |
|||
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 102 | 99 | 201 |
| >=65 years | 53 | 46 | 99 |
|
Age
[units: years] Mean ± Standard Deviation |
53.95 ± 18.15 | 57.7 ± 15.30 | 55.78 ± 16.91 |
|
Gender
[units: participants] |
|||
| Female | 76 | 71 | 147 |
| Male | 79 | 74 | 153 |
|
Region of Enrollment
[units: participants] |
|||
| United States | 155 | 145 | 300 |
Outcome Measures
More Information
Certain Agreements:
Limitations and Caveats
Results Point of Contact:
No publications provided
| All Principal Investigators ARE employed by the organization sponsoring the study. |
Limitations and Caveats
| Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data |
|---|
| No text entered. |
Results Point of Contact:
Name/Title: DaiWai M Olson, PhD RN
Organization: Duke University Health System
phone: (919) 668-3751
e-mail: Olson006@mc.duke.edu
Organization: Duke University Health System
phone: (919) 668-3751
e-mail: Olson006@mc.duke.edu
No publications provided
| Responsible Party: | Duke University |
| ClinicalTrials.gov Identifier: | NCT00734409 History of Changes |
| Other Study ID Numbers: | PRO00002117, DUHS parent 3930938 |
| Study First Received: | June 3, 2008 |
| Results First Received: | August 10, 2012 |
| Last Updated: | March 21, 2013 |
| Health Authority: | United States: Institutional Review Board |